We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioWa Licenses Anti-FGF8 Antibody From Kyowa Hakko Kogyo
News

BioWa Licenses Anti-FGF8 Antibody From Kyowa Hakko Kogyo

BioWa Licenses Anti-FGF8 Antibody From Kyowa Hakko Kogyo
News

BioWa Licenses Anti-FGF8 Antibody From Kyowa Hakko Kogyo

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioWa Licenses Anti-FGF8 Antibody From Kyowa Hakko Kogyo "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioWa has announced that it has licensed from Kyowa Hakko Kogyo Co., Ltd., its parent company, the exclusive worldwide rights except Asia to develop and commercialize Anti-Fibroblast Growth Factor 8 (FGF8) monoclonal antibody, a potential treatment for breast, ovarian and prostate cancers.

Under the terms of the agreement, BioWa expects to develop and commercialize anti-FGF8 antibody, which is currently in pre-clinical development.

In return, Kyowa Hakko Kogyo Co. has an option to develop and commercialize the product in Asia and will be responsible for all development activities and costs.

Under the terms of the agreement, BioWa retains all rights to anti-FGF8 antibody in non-Asia countries.

Each party has the right to use pre-clinical and clinical data generated by the other party for developing anti-FGF8 antibody in their respective territories.

“We are pleased to announce the second antibody addition to BioWa's pipeline of products,” said Dr. Nobuo Hanai, CEO & President of BioWa.

“BioWa is committed to building a strong antibody pipeline of large market value products through our own internal clinical development programs.”

“Anti-FGF8 antibody is an important addition to BioWa's portfolio, which now consists of two pre-clinical stage products being investigated across a broad range of indications.”

Advertisement